Metastatic melanoma or NSCLC with untreated brain metastases, and with any number of previous systematic treatments with the exception of previous inhibitors of PD-1, PD-L1, or PD-L2. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.